Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
1867
mi
from 98109
Memphis, TN
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Methodist University Hospital
1867
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
1682
mi
from 98109
Dallas, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
University of Texas Southwestern Medical Center
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
1661
mi
from 98109
Fort Worth, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Baylor All Saints Medical Center
1661
mi
from 98109
Fort Worth, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
1787
mi
from 98109
San Antonio, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Brooke Army Medical Center
1787
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
702
mi
from 98109
Salt Lake City, UT
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
University of Utah Health Sciences Center
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2326
mi
from 98109
Burlington, VT
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
University of Vermont
2326
mi
from 98109
Burlington, VT
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2409
mi
from 98109
Newport News, VA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Bon Secours Richmond Health System
2409
mi
from 98109
Newport News, VA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2349
mi
from 98109
Richmond, VA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Mcguire Va Medical Center
2349
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
4979
mi
from 98109
Aachen,
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Universitätsklinikum der RWTH Aachen
4979
mi
from 98109
Aachen,
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2262
mi
from 98109
New York, NY
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Mount Sinai Beth Israel Medical Center
2262
mi
from 98109
New York, NY
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
1785
mi
from 98109
Live Oak, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Pinnacle Clinical Research
1785
mi
from 98109
Live Oak, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2322
mi
from 98109
Washington,
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Sibley Memorial Hospital
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2322
mi
from 98109
Washington,
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Howard University
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
2402
mi
from 98109
Bronx, NY
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Montefiore Medical Center
2402
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
957
mi
from 98109
Pasadena, CA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
California Liver Research Institute
957
mi
from 98109
Pasadena, CA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
965
mi
from 98109
Rialto, CA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Inland Empire Liver Foundation
965
mi
from 98109
Rialto, CA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2177
mi
from 98109
Atlanta, GA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Piedmont Atlanta Hospital
2177
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1455
mi
from 98109
Clive, IA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Iowa Digestive Disease Center
1455
mi
from 98109
Clive, IA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2328
mi
from 98109
Baltimore, MD
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Digestive and Liver Disease Specialists; Mercy Medical Center
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1877
mi
from 98109
Germantown, TN
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Gastro One
1877
mi
from 98109
Germantown, TN
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1670
mi
from 98109
Arlington, TX
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Texas Clinical Research Institute
1670
mi
from 98109
Arlington, TX
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1786
mi
from 98109
San Antonio, TX
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
American Research Corporation at Texas Liver Institute
1786
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2733
mi
from 98109
Palmetto Bay, FL
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
IMIC
2733
mi
from 98109
Palmetto Bay, FL
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1930
mi
from 98109
Detroit, MI
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1450
mi
from 98109
Rochester, MN
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1394
mi
from 98109
Saint Paul, MN
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Minnesota Gastroenterology, P.A.
1394
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1508
mi
from 98109
Kansas City, MO
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Kansas City Gastroenterology & Hepatology
1508
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2341
mi
from 98109
Durham, NC
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Duke University Medical Center - Duke South Clinics
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2371
mi
from 98109
Philadelphia, PA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2371
mi
from 98109
Philadelphia, PA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Einstein Healthcare Network
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1890
mi
from 98109
Houston, TX
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Advanced Liver Therapies, Baylor College of Medicine
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
1787
mi
from 98109
San Antonio, TX
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Pinnacle Clinical Research
1787
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2434
mi
from 98109
Norfolk, VA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Digestive and Liver Disease Specialists
2434
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2350
mi
from 98109
Richmond, VA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Bon Secours Liver Institute of Virginia
2350
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2349
mi
from 98109
Richmond, VA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Mcguire Va Medical Center
2349
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
2
mi
from 98109
Seattle, WA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
University of Washington; Harborview Medical Center
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
mi
from 98109
Bonn,
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Universitätsklinikum Bonn
mi
from 98109
Bonn,
Click here to add this to my saved trials
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Status: Enrolling
Updated:  4/26/2018
1391
mi
from 98109
Lakewood, CO
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Status: Enrolling
Updated: 4/26/2018
DaVita Clinical Research- Colorado
1391
mi
from 98109
Lakewood, CO
Click here to add this to my saved trials
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Status: Enrolling
Updated:  4/26/2018
1391
mi
from 98109
Minneapolis, MN
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Status: Enrolling
Updated: 4/26/2018
DaVita Clinical Research- Minnesota
1391
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer
Status: Enrolling
Updated:  4/27/2018
1733
mi
from 98109
Chicago, IL
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer
Status: Enrolling
Updated: 4/27/2018
University of Chicago Comprehensive Cancer Center
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer
Status: Enrolling
Updated:  4/27/2018
1733
mi
from 98109
Chicago, IL
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer
Status: Enrolling
Updated: 4/27/2018
University of Illinois College of Medicine - Chicago
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer
Status: Enrolling
Updated:  4/27/2018
1450
mi
from 98109
Rochester, MN
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer
Status: Enrolling
Updated: 4/27/2018
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Trimodality Management of T1b Esophageal Cancers
Phase IIB Study of Trimodality Management of Clinical T1bN0M0 Cancers of the Esophagus
Status: Enrolling
Updated:  4/27/2018
1892
mi
from 98109
Houston, TX
Trimodality Management of T1b Esophageal Cancers
Phase IIB Study of Trimodality Management of Clinical T1bN0M0 Cancers of the Esophagus
Status: Enrolling
Updated: 4/27/2018
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes
Automated Evaluation of Gastrointestinal Symptoms (AEGIS): A Pragmatic Clinical Trial Evaluating the Impact of AEGIS on Clinical Outcomes
Status: Enrolling
Updated:  4/29/2018
962
mi
from 98109
Los Angeles, CA
Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes
Automated Evaluation of Gastrointestinal Symptoms (AEGIS): A Pragmatic Clinical Trial Evaluating the Impact of AEGIS on Clinical Outcomes
Status: Enrolling
Updated: 4/29/2018
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated:  4/30/2018
2134
mi
from 98109
Pittsburgh, PA
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated: 4/30/2018
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated:  4/30/2018
703
mi
from 98109
Salt Lake City, UT
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated: 4/30/2018
University of Utah
703
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated:  4/30/2018
2072
mi
from 98109
Birmingham, AL
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated: 4/30/2018
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated:  4/30/2018
1056
mi
from 98109
La Jolla, CA
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated: 4/30/2018
The University of California, San Diego
1056
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated:  4/30/2018
1723
mi
from 98109
Maywood, IL
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated: 4/30/2018
Loyola University
1723
mi
from 98109
Maywood, IL
Click here to add this to my saved trials
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated:  4/30/2018
2341
mi
from 98109
Durham, NC
Behavioral Therapy Of Obstetric Sphincter Tears
BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study
Status: Enrolling
Updated: 4/30/2018
Duke University
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials